The U.S. Supreme Court in June 2013 issued its decision on "reverse payment" settlements between brand-name and generic drug manufacturers. The case, FTC v. Actavis, involved an antitrust challenge to the settlement of patent infringement litigation brought under the Hatch-Waxman Act. Jeffery M. Cross, a Partner in the Litigation Practice Group, and Jill Anderson, leader of the Antitrust Litigation Team offer insights on the affect of the decision, in "Antitrust Challenge Permitted by FTC v. Actavis May Be Limited," published in the October/November 2013 issue of Today's General Counsel.
The full White Paper is attached.
Available Downloads
Related Articles
Related People
-
Partner
-
Partner